NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/ARC-EX Non-Invasive Spinal Cord Stimulation System
non-invasive-stimulation510k-clearedapproved

ARC-EX Non-Invasive Spinal Cord Stimulation System

Implant Type
non-invasive-stimulation
Electrodes
0
Channels
0
FDA Status
510k-cleared
Clinical Stage
Post-market (FDA 510(k) cleared December 2024; CE Mark September 2025)
Status
approved
About

The ARC-EX System is the world's first FDA-approved non-invasive spinal cord stimulation system for chronic spinal cord injury. It delivers programmed transcutaneous electrical stimulation to the cervical spinal cord via skin electrodes on the back of the neck, improving hand sensation and strength when used with functional task practice. In the Up-LIFT clinical trial (65 participants, 14 SCI centers), 90% improved upper limb strength or function, 87% reported quality of life improvement, with benefits demonstrated up to 34 years post-injury. Selected as TIME Magazine Best Invention 2024 and Fast Company 2025 World Changing Ideas.

Target Conditions
chronic incomplete spinal cord injury (C2-C8)hand and arm function restoration
Milestones
2024-12FDA 510(k) clearance; first FDA-approved non-invasive SCS for SCI
2024-12TIME Magazine Best Invention 2024
2025-09CE Mark certification under EU MDR
FDA Regulatory Pathway
No FDA Regulatory Status

This device does not have a current FDA designation. It may be a research tool, preclinical device, or consumer product not subject to FDA medical device regulation.

FDA Device Regulatory Guidance ↗